A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Patients With Breast Cancer

Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Patients With Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Balugrastim (Primary)
  • Indications Neutropenia
  • Focus Adverse reactions
  • Sponsors Jiangsu T-mab BioPharma
  • Most Recent Events

    • 15 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
    • 15 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 13 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top